<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832532</url>
  </required_header>
  <id_info>
    <org_study_id>CIN001Pilot 2GLP</org_study_id>
    <secondary_id>UL1RR026314</secondary_id>
    <nct_id>NCT01832532</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks</brief_title>
  <official_title>Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, controlled study.&#xD;
&#xD;
      The investigators are studying if the FDA approved diabetes medicine liraglutide (Victoza®)&#xD;
      can improve sleep apnea in adults. This study is testing liraglutide in 20 adults without&#xD;
      diabetes that are diagnosed with sleep apnea.The treatment group will be compared to a&#xD;
      control group of 10 adults without diabetes who have sleep apnea but will not use&#xD;
      liraglutide. Both groups will continue receiving standard of care for their sleep apnea as&#xD;
      prescribed by their managing sleep physician throughout their study participation.&#xD;
&#xD;
      Everyone in the study will have two study visits and one overnight sleep study for research.&#xD;
      Subjects who have not had a recent sleep study but otherwise qualify for the study, will have&#xD;
      an additional research sleep study to determine the baseline severity of their sleep apnea.&#xD;
      The study visits include fasting blood samples and breathing tests (pulmonary function test&#xD;
      and hypercapnic challenge). There will be weekly phone visits that include a questionnaire on&#xD;
      sleepiness. The group that takes liraglutide will check their blood sugar two times a day&#xD;
      while on the medicine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study aimed at measuring the change in obstructive apnea/hypopnea index in&#xD;
      non-diabetic patients being treated for the first time with the glucagon-like peptide-1&#xD;
      (GLP-1) agonist, Liraglutide. Sleep disordered breathing (SDB) consists of nocturnal alveolar&#xD;
      hypoventilation and / or obstructive sleep apnea which result from abnormalities in upper&#xD;
      airway tone and ventilation during sleep. The development of a new pharmacological treatment&#xD;
      for sleep disordered breathing (SDB) could bring a breakthrough discovery that will impact a&#xD;
      rapidly growing population of children and adults with this disorder. The investigators&#xD;
      hypothesize that GLP-1 plays a central role in the improvement of SDB and that the&#xD;
      administration of GLP-1 receptor agonist to patients with OSA will correct or improve SDB.&#xD;
&#xD;
        -  Hypothesis 1: Administration of Liraglutide to patients with severe OSA defined as apnea&#xD;
           hypopnea index ≥ 8 /hr. will result in a mean reduction in the index by a minimum of 50%&#xD;
           after 4 weeks.&#xD;
&#xD;
        -  Hypothesis 2: Administration of Liraglutide will result in significant increase in&#xD;
           Orexin level, decrease in leptin, decrease in Epworth Sleepiness Scale (ESS) score and&#xD;
           increase in carbon dioxide (CO2) chemosensitivity.&#xD;
&#xD;
      This is an open label, non-randomized, controlled pilot study. Subjects are heavy to obese&#xD;
      non-diabetic adults that are diagnosed with sleep apnea. 20 subjects will be treated with&#xD;
      liraglutide for 4 weeks and compared to 10 untreated controls.&#xD;
&#xD;
      Study time points are baseline and 4 weeks post treatment. Study procedures include pre and&#xD;
      post treatment: fasting blood for glucose, hemoglobin A1C (HbA1C), Orexin and leptin; ESS&#xD;
      questionnaire; pulmonary function test and hypercapnic challenge. The procedures also include&#xD;
      a post treatment overnight research sleep study to measure change in apnea index from&#xD;
      diagnostic sleep study done previous to study enrollment or if needed, the baseline research&#xD;
      sleep study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Apnea Hypopnea Index (AHI) From Baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change in the number of apneas plus hypopnea events per hour of sleep from baseline at end of study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Sleep Disordered Breathing</condition>
  <arm_group>
    <arm_group_label>Treatment group- liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose</description>
    <arm_group_label>Treatment group- liraglutide</arm_group_label>
    <other_name>Other name- Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  Diagnosis of severe obstructive sleep apnea (OSA) AHI ≥ 8 /hour of sleep&#xD;
&#xD;
          -  Ability and willingness to comply with all protocol procedures e.g. correct handling&#xD;
             of trial product, compliance to visit schedule&#xD;
&#xD;
          -  BMI of ≥ 27&#xD;
&#xD;
          -  For Cohort 1: If female of childbearing capacity, willing to use acceptable birth&#xD;
             control during use of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A major medical condition such as renal or hepatic failure&#xD;
&#xD;
          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl&#xD;
             peptidase-4 inhibitors or insulin within the last 3 months prior to screening&#xD;
&#xD;
          -  Diagnosis of type 1 or type 2 diabetes per judgment of the investigator&#xD;
&#xD;
          -  BMI &lt; 27&#xD;
&#xD;
          -  History of glycosylated hemoglobin (HbA1c) equal to or above 6.5%&#xD;
&#xD;
          -  Significant craniofacial abnormalities that may cause OSA&#xD;
&#xD;
          -  Respiratory and neuromuscular diseases that could interfere with the results of the&#xD;
             trial in the opinion of the investigator&#xD;
&#xD;
          -  Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone or drugs in the&#xD;
             incretin family within the previous 3 months prior to screening&#xD;
&#xD;
          -  Previous surgical treatment for obesity&#xD;
&#xD;
          -  Familial or personal history of Multiple Endocrine Neoplasia type 2 or familial&#xD;
             Medullary Thyroid Carcinoma&#xD;
&#xD;
          -  Personal or immediate family history of thyroid cancer&#xD;
&#xD;
          -  History of chronic pancreatitis or idiopathic acute pancreatitis&#xD;
&#xD;
          -  History of Major Depressive Disorder or suicide attempts&#xD;
&#xD;
          -  Systolic blood pressure equal to or above 160 mmHg and/or diastolic blood pressure&#xD;
             equal to or above 100 mmHg&#xD;
&#xD;
          -  History of alcoholism&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raouf Amin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>September 26, 2020</last_update_submitted>
  <last_update_submitted_qc>September 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep Apnea</keyword>
  <keyword>Sleep Disordered Breathing</keyword>
  <keyword>liraglutide</keyword>
  <keyword>glucagon-like peptide-1 agonist</keyword>
  <keyword>Orexin</keyword>
  <keyword>leptin,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Manuscript is in progress.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrollment fell short of goal for each cohort</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group- Liraglutide</title>
          <description>Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.&#xD;
liraglutide: daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group- Liraglutide</title>
          <description>Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.&#xD;
liraglutide: daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Control group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="8"/>
                    <measurement group_id="B2" value="44.5" spread="10.6"/>
                    <measurement group_id="B3" value="46.2" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Apnea Hypopnea Index (AHI) From Baseline</title>
        <description>Change in the number of apneas plus hypopnea events per hour of sleep from baseline at end of study.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group- Liraglutide</title>
            <description>Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.&#xD;
liraglutide: daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apnea Hypopnea Index (AHI) From Baseline</title>
          <description>Change in the number of apneas plus hypopnea events per hour of sleep from baseline at end of study.</description>
          <units>apnea / hypopnea events per hour sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="30"/>
                    <measurement group_id="O2" value="34" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group- Liraglutide</title>
          <description>Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.&#xD;
liraglutide: daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Control group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raouf Amin, MD</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>(513) 636-7945</phone>
      <email>Raouf.Amin@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

